Pretomanid 200 mg Receives EMA Recommendation For Approval, Offering Hope For Drug-Resistant TB Patients
Pretomanid 200 mg tablets are a novel nitroimidazooxazine-based anti-tuberculosis drug that kills Mycobacterium tuberculosis by inhibiting mycobacterial cell wall synthesis. Its unique dual mechanism of action makes it an excellent candidate for drug-resistant TB.
Based on clinical trial data, Pretomanid drug in combination with bedaquiline and linezolid has demonstrated significant efficacy in the treatment of extensively drug-resistant TB.
In a study involving 109 patients, Pretomanid was shown to be effective in treating extensively drug-resistant TB.
Treatment Regimen And Precautions
The recommended dose of Pretomanid drug is 200 mg orally once daily for 26 weeks in combination with bedaquiline and linezolid.
Bedaquiline is initially dosed at 400 mg daily and adjusted to 200 mg three times weekly after two weeks; linezolid is dosed at 600 mg or 1200 mg daily, depending on patient tolerance.
The dose of bedaquiline is 600 mg or 1200 mg per day, depending on patient tolerance.
Pretomanid 200 mg’s Outlook For The future
The approval of Pretomanid not only provides a new treatment option for drug-resistant TB patients, but also gives new impetus to global TB prevention and control efforts.
With further research and promotion, this drug is expected to save more lives globally and contribute to the goal of ending TB.
Pretomanid 200 mg Ushers In A New Era For TB Treatment
On March 7, 2025, the global innovative anti-tuberculosis drug Pretomanid® Pretomanid Tablets (Pretomanid) officially arrived in China, and was supplied by Shenyang Red Flag Pharmaceutical Co.
This marks that drug-resistant tuberculosis patients in China will be able to apply for the use of this drug through standardized channels, and drug-resistant tuberculosis treatment has formally entered a new era of 6-month short-course treatment.
FINANCE.SINA.COM.
Developed by the Global Alliance for TB Drug Development (TB Alliance), protomanil is a nitroimidazole antibiotic with a unique structure and anti-tuberculosis mechanism of action, and high specificity for Mycobacterium tuberculosis (MTB).
Food and Drug Administration (FDA) approved the marketing of pronominal for use in combination with bedaquiline and linezolid in treating specific patients with highly drug-resistant tuberculosis. The drug was also selected for the 2020 Galen Award for “Best Drug.”
However, DengYue’s efforts to increase the affordability of the medicine are critical to ensuring that more patients benefit from it.
We welcome you to reach out to us to get Pretomanid cost. DengYueMedicine is here to provide detailed medicine information, pricing, and support to ensure a smooth and reliable buying experience.
Feel free to contact us anytime to discuss your needs or ask any questions about the medicine.
Information from DengYueMed, China Drug Import and Export Wholesaler offers this information as a guide, not a substitute for professional medical advice. Consult your doctor before any treatment.
